Stay updated on Safety of SNA-120 in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.

Latest updates to the Safety of SNA-120 in Psoriasis Clinical Trial page
- Check4 days agoChange DetectedAdded Revision: v3.4.2. Removed the notice about government funding and the earlier Revision: v3.4.1.SummaryDifference0.4%

- Check11 days agoChange DetectedNotice added: a government-funding lapse advisory appears on the page and the revision is updated to v3.4.1 (previously v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check18 days agoChange DetectedAdded a Show glossary option and updated QC-related text and revision numbers (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0) with capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check32 days agoChange DetectedRevision notes show an addition of Revision: v3.3.4 and a deletion of Revision: v3.3.3.SummaryDifference0.0%

- Check54 days agoChange DetectedA consolidated Locations section has been added, listing all participating sites by state/province and country (e.g., Alabama, California, Florida, British Columbia, Ontario, Quebec). The previous location subsections were removed, and the study record updated to Revision: v3.3.3.SummaryDifference1%

- Check83 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study content or user-facing information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Safety of SNA-120 in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.